FDA Approves Alternative to Warfarin — Rivaroxaban (Xarelto) Approved for Atrial Fibrillation Stroke Prevention
Posted Nov 07 2011 8:08am
The US Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those with non-valvular atrial fibrillation (afib unrelated to heart valve problems). Xarelto is now the second oral alternative to warfarin (Coumadin) and offers an option for those unable to take warfarin or dabigatran.
Xarelto is the first once-a-day alternative to warfarin and does not require the regular blood testing that warfarin does. Learn more about the approval of Xarelto at: